{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:16:57Z","timestamp":1780993017168,"version":"3.54.1"},"reference-count":25,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>OBJECTIVE\u2014The inflammation marker YKL-40 is elevated in patients with type 2 diabetes and is associated with atherosclerosis and increased cardiovascular mortality. In the present study, YKL-40 levels were examined in patients with type 1 diabetes with increasing levels of albuminuria, known to be associated with an increased risk of cardiovascular disease.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014A total of 149 patients with type 1 diabetes attending Steno Diabetes Center were examined: 58 had normoalbuminuria (urinary albumin excretion rate &amp;lt;30 mg\/24 h), 46 had persistent microalbuminuria (urinary albumin excretion rate 30\u2013300 mg\/24 h), and 45 had persistent macroalbuminuria\/diabetic nephropathy (urinary albumin excretion rate &amp;gt;300 mg\/24 h). The control group consisted of 55 healthy individuals. Groups were matched according to sex and duration of diabetes (&amp;gt;30 years).<\/jats:p>\n               <jats:p>RESULTS\u2014Median levels [interquartile range] of serum YKL-40 were significantly higher in normoalbuminuria versus control (37 [29\u201352] vs. 53 [32\u2013105] ng\/ml, P &amp;lt; 0.01) and were increasing with increasing levels of albuminuria (microalbuminuria 74 [45\u2013160] ng\/ml and diabetic nephropathy 117 [68\u2013215] ng\/ml; P &amp;lt; 0.001 for all comparisons). YKL-40 levels correlated with the urinary albumin-to-creatinine ratio in the total group of participants (r2 = 0.25, P &amp;lt; 0.001). Significant but weak intercorrelations of YKL-40 were found with age, diastolic blood pressure, A1C, and serum creatinine. After adjustment for significant covariates, albuminuria was significantly associated with YKL-40 levels (P &amp;lt; 0.001).<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014YKL-40 levels are elevated in patients with type 1 diabetes with an independent association between increasing YKL-40 levels and increasing levels of albuminuria. The present study is the first to suggest a role of YKL-40 in the gradually progressing vascular complications in patients with type 1 diabetes.<\/jats:p>","DOI":"10.2337\/dc08-1144","type":"journal-article","created":{"date-parts":[[2008,10,29]],"date-time":"2008-10-29T02:24:14Z","timestamp":1225247054000},"page":"323-328","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":115,"title":["YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria"],"prefix":"10.2337","volume":"32","author":[{"given":"Camilla Noelle","family":"Rathcke","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark"},{"name":"Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031219180187500_R1","doi-asserted-by":"crossref","unstructured":"Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol\u200819: 1992\u20131997, 1999","DOI":"10.1161\/01.ATV.19.8.1992"},{"key":"2022031219180187500_R2","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA\u2008286:421\u2013426, 2001","DOI":"10.1001\/jama.286.4.421"},{"key":"2022031219180187500_R3","doi-asserted-by":"crossref","unstructured":"Rossing P, Hougaard P, Parving H-H: Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int\u200868:1446\u20131450, 2005","DOI":"10.1111\/j.1523-1755.2005.00556.x"},{"key":"2022031219180187500_R4","doi-asserted-by":"crossref","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care\u200816:434\u2013444, 1993","DOI":"10.2337\/diacare.16.2.434"},{"key":"2022031219180187500_R5","doi-asserted-by":"crossref","unstructured":"Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia\u200846:760\u2013765, 2003","DOI":"10.1007\/s00125-003-1116-6"},{"key":"2022031219180187500_R6","doi-asserted-by":"crossref","unstructured":"Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving H-H: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care\u200826:1258\u20131264, 2003","DOI":"10.2337\/diacare.26.4.1258"},{"key":"2022031219180187500_R7","doi-asserted-by":"crossref","unstructured":"Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med\u2008330:15\u201318, 1994","DOI":"10.1056\/NEJM199401063300103"},{"key":"2022031219180187500_R8","doi-asserted-by":"crossref","unstructured":"Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z, Keen H: The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med\u200816:466\u2013471, 1999","DOI":"10.1046\/j.1464-5491.1999.00076.x"},{"key":"2022031219180187500_R9","doi-asserted-by":"crossref","unstructured":"Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia\u200832:219\u2013226, 1989","DOI":"10.1007\/BF00285287"},{"key":"2022031219180187500_R10","doi-asserted-by":"crossref","unstructured":"Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation\u2008105:1135\u20131143, 2002","DOI":"10.1161\/hc0902.104353"},{"key":"2022031219180187500_R11","doi-asserted-by":"crossref","unstructured":"Rathcke CN, Vestergaard H: YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res\u200855:221\u2013227, 2006","DOI":"10.1007\/s00011-006-0076-y"},{"key":"2022031219180187500_R12","doi-asserted-by":"crossref","unstructured":"Millis AJ, Hoyle M, Kent L: In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol\u2008127:366\u2013372, 1986","DOI":"10.1002\/jcp.1041270304"},{"key":"2022031219180187500_R13","doi-asserted-by":"crossref","unstructured":"Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res\u2008250:168\u2013173, 1999","DOI":"10.1006\/excr.1999.4511"},{"key":"2022031219180187500_R14","doi-asserted-by":"crossref","unstructured":"Shackelton LM, Mann DM, Millis AJ: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem\u2008270:13076\u201313083, 1995","DOI":"10.1074\/jbc.270.22.13076"},{"key":"2022031219180187500_R15","doi-asserted-by":"crossref","unstructured":"Rathcke CN, Johansen JS, Vestergaard H: YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res\u200855:53\u201359, 2006","DOI":"10.1007\/s00011-005-0010-8"},{"key":"2022031219180187500_R16","unstructured":"Rathcke CN, Raymond I, Kistorp C, Faber J, Vestergaard H: The inflammation marker YKL-40 is elevated in patients with type 2 diabetes and is associated with an increased mortality rate in normal individuals after adjustment for risk factors of cardiovascular events (Abstract). Diabetologia\u200850:s103, 2007"},{"key":"2022031219180187500_R17","doi-asserted-by":"crossref","unstructured":"Jager A, van HV, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol\u200822:593\u2013598, 2002","DOI":"10.1161\/01.ATV.0000013786.80104.D4"},{"key":"2022031219180187500_R18","doi-asserted-by":"crossref","unstructured":"Schalkwijk CG, Stehouwer CD: Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond)\u2008109:143\u2013159, 2005","DOI":"10.1042\/CS20050025"},{"key":"2022031219180187500_R19","doi-asserted-by":"crossref","unstructured":"Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD: Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia\u200848:370\u2013378, 2005","DOI":"10.1007\/s00125-004-1628-8"},{"key":"2022031219180187500_R20","doi-asserted-by":"crossref","unstructured":"Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving H-H, Rossing P: Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care\u200831:1170\u20131176, 2008","DOI":"10.2337\/dc07-1960"},{"key":"2022031219180187500_R21","doi-asserted-by":"crossref","unstructured":"Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T: Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes\u200856:2790\u20132796, 2007","DOI":"10.2337\/db07-0784"},{"key":"2022031219180187500_R22","doi-asserted-by":"crossref","unstructured":"Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S: Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis\u200818:391\u2013396, 2007","DOI":"10.1097\/MCA.0b013e328241d991"},{"key":"2022031219180187500_R23","doi-asserted-by":"crossref","unstructured":"Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS: Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis\u200819:257\u2013263, 2008","DOI":"10.1097\/MCA.0b013e3282f40dd5"},{"key":"2022031219180187500_R24","unstructured":"Johansen JS: Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull\u200853:172\u2013209, 2006"},{"key":"2022031219180187500_R25","doi-asserted-by":"crossref","unstructured":"Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E: YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat\u2008112:275\u2013285, 2008","DOI":"10.1007\/s10549-007-9870-7"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/32\/2\/323\/600480\/zdc00209000323.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/32\/2\/323\/600480\/zdc00209000323.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T20:43:46Z","timestamp":1647117826000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/32\/2\/323\/27532\/YKL-40-a-Marker-of-Inflammation-and-Endothelial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc08-1144","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}